v3.26.1
Note 4 - Collaboration Agreements (Details Textual)
¥ in Billions
1 Months Ended 3 Months Ended
Nov. 30, 2020
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
CNY (¥)
Revenue from Contract with Customer, Including Assessed Tax   $ 0 $ 0    
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]          
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received       $ 101,479,000 ¥ 0.7
Collaboration Agreement, Maximum Commercial Milestones to be Received       57,988,000 0.4
Revenue from Contract with Customer, Excluding Assessed Tax   0 0    
Revenues $ 780,000 3,000      
Revenue from Contract with Customer, Including Assessed Tax   $ 500,000 $ 500,000    
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | Maximum [Member]          
Collaborative Arrangement, Equity Investment $ 10,000        
Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member] | Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member]          
Collaboration Agreement, Upfront Cash Payment       $ 28,994,000 ¥ 0.2